| Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity B Meng, A Abdullahi, IATM Ferreira, N Goonawardane, A Saito, I Kimura, ... Nature 603 (7902), 706-714, 2022 | 865 | 2022 |
| Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 DA Collier, IATM Ferreira, P Kotagiri, RP Datir, EY Lim, E Touizer, B Meng, ... Nature 596 (7872), 417-422, 2021 | 618 | 2021 |
| Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission L Rivett, S Sridhar, D Sparkes, M Routledge, NK Jones, S Forrest, ... elife 9, e58728, 2020 | 595 | 2020 |
| NOTCH1 mediates a switch between two distinct secretomes during senescence M Hoare, Y Ito, TW Kang, MP Weekes, NJ Matheson, DA Patten, S Shetty, ... Nature cell biology 18 (9), 979-992, 2016 | 444 | 2016 |
| Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 424 | 2021 |
| Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells IA Tchasovnikarova, RT Timms, NJ Matheson, K Wals, R Antrobus, ... Science 348 (6242), 1481-1485, 2015 | 305 | 2015 |
| Increased demand for NAD+ relative to ATP drives aerobic glycolysis A Luengo, Z Li, DY Gui, LB Sullivan, M Zagorulya, BT Do, R Ferreira, ... Molecular cell 81 (4), 691-707. e6, 2021 | 285 | 2021 |
| Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease L Bergamaschi, F Mescia, L Turner, AL Hanson, P Kotagiri, BJ Dunmore, ... Immunity 54 (6), 1257-1275. e8, 2021 | 276 | 2021 |
| How does SARS-CoV-2 cause COVID-19? NJ Matheson, PJ Lehner Science 369 (6503), 510-511, 2020 | 219 | 2020 |
| Covid-19: should the public wear face masks? B Javid, MP Weekes, NJ Matheson Bmj 369, 2020 | 199 | 2020 |
| Cell surface proteomic map of HIV infection reveals antagonism of amino acid metabolism by Vpu and Nef NJ Matheson, J Sumner, K Wals, R Rapiteanu, MP Weekes, R Vigan, ... Cell host & microbe 18 (4), 409-423, 2015 | 189 | 2015 |
| Neuraminidase inhibitors for preventing and treating influenza in children NJ Matheson, A Harnden, R Perera, A Sheikh, M Symmonds‐Abrahams Cochrane Database of Systematic Reviews, 2007 | 172* | 2007 |
| FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 T Brevini, M Maes, GJ Webb, BV John, CD Fuchs, G Buescher, L Wang, ... Nature 615 (7950), 134-142, 2023 | 151 | 2023 |
| Vaccines for preventing influenza in healthy children S Smith, V Demicheli, C Di Pietrantonj, AR Harnden, T Jefferson, ... Evidence‐Based Child Health: A Cochrane Review Journal 1 (2), 367-522, 2006 | 142 | 2006 |
| An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles A Ortiz, J Gui, F Zahedi, P Yu, C Cho, S Bhattacharya, CJ Carbone, Q Yu, ... Cancer cell 35 (1), 33-45. e6, 2019 | 133 | 2019 |
| Neural stem cells traffic functional mitochondria via extracellular vesicles L Peruzzotti-Jametti, JD Bernstock, CM Willis, G Manferrari, R Rogall, ... PLoS biology 19 (4), e3001166, 2021 | 119 | 2021 |
| Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report MS Buckland, JB Galloway, CN Fhogartaigh, L Meredith, NM Provine, ... Nature communications 11 (1), 6385, 2020 | 109 | 2020 |
| Temporal proteomic analysis of HIV infection reveals remodelling of the host phosphoproteome by lentiviral Vif variants EJD Greenwood, NJ Matheson, K Wals, DJH van den Boomen, ... Elife 5, e18296, 2016 | 100 | 2016 |
| Promiscuous targeting of cellular proteins by Vpr drives systems-level proteomic remodeling in HIV-1 infection EJD Greenwood, JC Williamson, A Sienkiewicz, A Naamati, NJ Matheson, ... Cell reports 27 (5), 1579-1596. e7, 2019 | 86 | 2019 |
| Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection NK Jones, L Rivett, S Seaman, RJ Samworth, B Warne, C Workman, ... Elife 10, e68808, 2021 | 83 | 2021 |
Paul LehnerProfessor of Immunobiology Cambridge UniversityVerified email at cam.ac.uk
